59493
document
The efficacy , safety and cost-effectiveness of hydrotalcite versus esomeprazole in on-demand therapy of NERD : A multicenter , randomized , open-label study in China . OBJECTIVE The aim of the study was to investigate whether hydrotalcite was comparable to esomeprazole , a proton pump inhibitor , in on-demand therapy for non-erosive reflux disease ( NERD ) . METHODS This was a multicenter , randomized , open-label clinical trial with initial and on-demand therapy . Patients who had complete symptom relief in the initial therapy were randomized to either hydrotalcite or esomeprazole in the on-demand therapy . The percentage of patients who quit on-demand therapy in the two groups and the cost-effectiveness of the treatment were evaluated as primary end points . The rate of symptom relief and the improvement of symptom score for initial therapy and the weekly average symptom score and weekly average number of days on treatment for on-demand therapy were evaluated as secondary end points . RESULTS In total , 398 patients were recruited in the initial therapy group , among whom 253 were included in on-demand therapy , with 127 patients in the hydrotalcite group and the remaining 126 in the esomeprazole group . 14 ( 11.0 % ) patients in the hydrotalcite group and six ( 4.8 % ) in the esomeprazole group quit the on-demand therapy due to unsatisfactory symptom control ( P = 0.065 ) . Cost-effectiveness calculated as the ratio of the cost of hydrotalcite to that of esomeprazole ( per person/day ) was 35.3 % in the on-demand therapy . Similar number of patients achieved symptom relief in both groups . CONCLUSION Hydrotalcite is a good option of on-demand therapy for NERD patients due to its cost-effectiveness and speed of action .
59494
Intervention_Pharmacological
hydrotalcite
59495
Intervention_Pharmacological
esomeprazole
59496
Intervention_Pharmacological
hydrotalcite
59497
Intervention_Pharmacological
esomeprazole
59498
Intervention_Pharmacological
hydrotalcite
59499
Intervention_Pharmacological
esomeprazole
59500
Intervention_Pharmacological
hydrotalcite
59501
Intervention_Pharmacological
esomeprazole
59502
Intervention_Pharmacological
hydrotalcite
59503
Intervention_Pharmacological
esomeprazole
59504
Outcome_Other
efficacy
59505
Outcome_Other
safety
59506
Outcome_Other
cost-effectiveness
59507
Outcome_Other
patients who quit
59508
Outcome_Other
cost-effectiveness
59509
Outcome_Physical
rate of symptom relief
59510
Outcome_Physical
improvement of symptom score
59511
Outcome_Mental
weekly average number of days
59512
Outcome_Other
quit
59513
Participant_Condition
398 patients were recruited in the initial therapy group , among whom 253 were included in on-demand therapy , with 127 patients in the hydrotalcite group and the remaining 126 in the esomeprazole group .